Press Resease

Immuno-oncology Therapy Market by Therapy Type (Monoclonal Antibodies, Immune Checkpoint Inhibitors (PD-1/PD-L1 and CTLA-4), Immune System Modulators, and Cancer Vaccines) and by Therapeutic Areas, for Hospitals, Clinics, ASC’s and Cancer Research Institutes: Global Industry Perspective, Comprehensive Analysis and Forecast, 2016 - 2022

Published Date: 17-Jan-2018 Category: Pharmaceutical Report Format : PDF Pages: 110 Report Code: ZMR-2534 Status : Published

Global immuno-oncology therapy market is expected to reach USD 97.34 billion by end of 2022, growing at a CAGR of 14.6% between 2017 and 2022.

Description

The report covers forecast and analysis for the immuno-oncology therapy market on a global and regional level. The study provides historic data of 2016 along with a forecast from 2017 to 2022 based revenue (USD Billion). The study includes drivers and restraints for the immuno-oncology therapy market along with the impact they have on the demand over the forecast period. Additionally, the report includes the study of opportunities available in the immuno-oncology therapy market on a global level.

In order to give the users of this report a comprehensive view of the immuno-oncology therapy market, we have included competitive landscape and analysis of Porter’s Five Forces model for the market. The study encompasses a market attractiveness analysis, wherein therapy type segment, therapeutic area segment, and end-user segments are benchmarked based on their market size, growth rate, and general attractiveness.

The report provides company market share analysis in order to give a broader overview of the key players in the market. In addition, the report also covers key strategic developments of the market including acquisitions & mergers, new technology launch, agreements, partnerships, collaborations & joint ventures, research & development, technology and regional expansion of major participants involved in the market on the global and regional basis. Moreover, the study covers price trend analysis, the product portfolio of various companies according to the region.

The study provides a decisive view on the immuno-oncology therapy market by segmenting the market based on therapy type, therapeutic area, end-user, and regions. All the segments have been analyzed based on present and future trends and the market is estimated from 2016 to 2022. Based on therapy type the market is segmented into monoclonal antibodies, immune checkpoint inhibitors (PD1/ PDL1 and CTLA-4), immune system modulators, cancer vaccines and others. Based on the therapeutic area the market is segmented into lung cancer, colorectal cancer, breast cancer, prostate cancer, melanoma, blood cancer and other cancers. Key end-users covered under this study include hospitals, clinics, ASC’s and cancer research institutes. The regional segmentation includes the current and forecast demand for North America, Europe, Asia Pacific, Latin America and Middle East & Africa with its further bifurcation into major countries including the U.S., Canada, Rest of North America, U.K., Germany, France, Italy, Spain, Russia, Rest of Europe, China, Japan, India, Australia, Rest of Asia Pacific, Brazil, Mexico, Argentina, Rest of Latin America, Saudi Arabia, UAE, Qatar, South Africa and Rest of Middle East and Africa. This segmentation includes demand for immuno-oncology therapy market based on individual therapy type, therapeutic area and end-users in all the regions and countries.

The report also includes detailed profiles of end players such as Amgen, Inc., AstraZeneca Plc., Bristol-Myers Squibb Company, Eli Lilly and Company, F.Hoffmann-La Roche Ltd., GlaxoSmithKline Plc., Janssen Biotech, Merck and Co., Novartis AG, Pfizer, Inc., Sanofi, Spectrum Pharmaceuticals, Inc. and Takeda Pharmaceuticals.

This report segments the global immuno-oncology therapy market as follows:

Global Immuno-oncology Therapy Market: Therapy Type Segment Analysis

  • Monoclonal Antibodies
  • Immune Checkpoint Inhibitors
    • PD-1/ PD-L1
    • CTLA-4
  • Immune System Modulators
  • Cancer Vaccines
  • Others

Global Immuno-oncology Therapy Market: Therapeutic Area Segment Analysis

  • Lung Cancer
  • Colorectal Cancer
  • Breast Cancer
  • Prostate Cancer
  • Melanoma
  • Blood Cancer
  • Others Cancers

Global Immuno-oncology Therapy Market: End-user Segment Analysis

  • Hospitals
  • Clinics
  • Ambulatory Surgical Centers (ASC’s)
  • Cancer Research Institutes

Global Immuno-oncology Therapy Market: Regional Segment Analysis

  • North America
    • The U.S.
  • Europe
    • UK
    • France
    • Germany
  • Asia Pacific
    • China
    • Japan
    • India
  • Latin America
    • Brazil
  • Middle East and Africa

Table Of Content

  • Chapter 1. Introduction
    • 1.1. Report description and scope
    • 1.2. Research scope
    • 1.3. Research methodology
      • 1.3.1. Market research process
      • 1.3.2. Market research methodology
  • Chapter 2. Executive Summary
    • 2.1. Global Immuno-oncology Therapy Market, 2016 – 2022 (USD Billion)
    • 2.2. Global Immuno-oncology Therapy Market: Snapshot
  • Chapter 3. Immuno-oncology Therapy Market– Market Dynamics
    • 3.1. Introduction
    • 3.2. Market Drivers
      • 3.2.1. Global immuno-oncology therapy market drivers: Impact analysis
      • 3.2.2. Highly Promising Treatment Pipeline
      • 3.2.3. Increase in Number of Patients Suffering from Various Cancers
      • 3.2.4. Greater Efficiency Over Conventional Treatment Methods
    • 3.3. Market Restraints
      • 3.3.1. Global immuno-oncology therapy market restraints: Impact analysis
      • 3.3.2. High Level of Attrition within the Development Cycles
      • 3.3.3. Stringent Regulatory Framework
      • 3.3.4. Lack of Awareness of Immunotherapy
    • 3.4. Opportunities
      • 3.4.1. Developed Economies Showing Higher Development Rates
    • 3.5. Porter’s five forces analysis
      • 3.5.1. Bargaining power of suppliers
      • 3.5.2. Bargaining power of buyers
      • 3.5.3. Threat from new entrants
      • 3.5.4. Threat from new substitutes
      • 3.5.5. Degree of competition
    • 3.6. Market attractiveness analysis
      • 3.6.1. Market attractiveness analysis, by therapy type segment
      • 3.6.2. Market attractiveness analysis, by end-user segment
      • 3.6.3. Market attractiveness analysis, by regional segment
  • Chapter 4. Global Immuno-oncology Therapy Market– Competitive Landscape
    • 4.1. Company Market Share Analysis
      • 4.1.1. Global immuno-oncology therapy market: company market share, 2016
    • 4.2. Strategic Development
      • 4.2.1. Acquisitions & Mergers
      • 4.2.2. New Therapy Launch
      • 4.2.3. Agreements, Partnerships, Collaborations and Joint Ventures
      • 4.2.4. Research and Development and Regional Expansion
    • 4.3. Price Trend Analysis
  • Chapter 5. Global Immuno-oncology Therapy Market– Therapy Type Segment Analysis
    • 5.1. Global immuno-oncology therapy market: therapy type overview
      • 5.1.1. Global immuno-oncology therapy market revenue share, by therapy type, 2016 and 2022
    • 5.2. Monoclonal Antibodies
      • 5.2.1. Global immuno-oncology therapy market for monoclonal antibodies market, 2016 – 2022 (USD Billion)
    • 5.3. Immune Checkpoint Inhibitors
      • 5.3.1. Global immuno-oncology therapy market for immune checkpoint inhibitors market, 2016 – 2022 (USD Billion)
        • 5.3.1.1. Global immuno-oncology therapy market for PD1/ PDL1 market, 2016 – 2022 (USD Billion)
        • 5.3.1.2. Global immuno-oncology therapy market for CTLA-4 market, 2016 – 2022 (USD Billion)
    • 5.4. Immune System Modulators
      • 5.4.1. Global immuno-oncology therapy market for immune system modulators market, 2016 – 2022 (USD Billion)
    • 5.5. Cancer Vaccines
      • 5.5.1. Global immuno-oncology therapy market for cancer vaccines market, 2016 – 2022 (USD Billion)
    • 5.6. Others
      • 5.6.1. Global immuno-oncology therapy market for others market, 2016 – 2022 (USD Billion)
  • Chapter 6. Global Immuno-oncology Therapy Market– Therapeutic Area Segment Analysis
    • 6.1. Global immuno-oncology therapy market: therapeutic area overview
      • 6.1.1. Global immuno-oncology therapy market revenue share, by therapeutic area, 2016 and 2022
    • 6.2. Lung Cancer
      • 6.2.1. Global immuno-oncology therapy market for lung cancer market, 2016 – 2022 (USD Billion)
    • 6.3. Colorectal Cancer
      • 6.3.1. Global immuno-oncology therapy market for colorectal cancer market, 2016 – 2022 (USD Billion)
    • 6.4. Breast Cancer
      • 6.4.1. Global immuno-oncology therapy market for breast cancer market, 2016 – 2022 (USD Billion)
    • 6.5. Prostate Cancer
      • 6.5.1. Global immuno-oncology therapy market for prostate cancer market, 2016 – 2022 (USD Billion)
    • 6.6. Melanoma
      • 6.6.1. Global immuno-oncology therapy market for melanoma market, 2016 – 2022 (USD Billion)
    • 6.7. Blood Cancer
      • 6.7.1. Global immuno-oncology therapy market for blood cancer market, 2016 – 2022 (USD Billion)
    • 6.8. Other Cancers
      • 6.8.1. Global immuno-oncology therapy market for other cancers market, 2016 – 2022 (USD Billion)
  • Chapter 7. Global Immuno-oncology Therapy Market– End-User Segment Analysis
    • 7.1. Global immuno-oncology therapy market: end-user overview
      • 7.1.1. Global immuno-oncology therapy market revenue share, by end-user, 2016 and 2022
    • 7.2. Hospitals
      • 7.2.1. Global immuno-oncology therapy market for hospitals 2016 – 2022 (USD Billion)
    • 7.3. Clinics
      • 7.3.1. Global immuno-oncology therapy market for clinics, 2016 – 2022 (USD Billion)
    • 7.4. Ambulatory Surgical Centers (ASC’s)
      • 7.4.1. Global immuno-oncology therapy market for ambulatory surgical centers, 2016 – 2022 (USD Billion)
    • 7.5. Cancer Research Institutes
      • 7.5.1. Global immuno-oncology therapy market for cancer research institutes end-users, 2016 – 2022 (USD Billion)
  • Chapter 8. Global Immuno-oncology Therapy Market– Regional Segment Analysis
    • 8.1. Global immuno-oncology therapy market: regional overview
      • 8.1.1. Global immuno-oncology therapy market revenue share, by region, 2016 and 2022
    • 8.2. North America
      • 8.2.1. North America immuno-oncology therapy market revenue, by therapy type, 2016 – 2022 (USD Billion)
      • 8.2.2. North America immuno-oncology therapy market revenue, by therapeutic area, 2016 – 2022 (USD Billion)
      • 8.2.3. North America immuno-oncology therapy market revenue, by end-user, 2016 – 2022 (USD Billion)
      • 8.2.4. U.S.
        • 8.2.4.1. U.S. Immuno-oncology therapy market revenue, by therapy type, 2016 – 2022 (USD Billion)
        • 8.2.4.2. U.S. Immuno-oncology therapy market revenue, by therapeutic area, 2016 – 2022 (USD Billion)
        • 8.2.4.3. U.S. Immuno-oncology therapy market revenue, by end-user, 2016 – 2022 (USD Billion)
      • 8.2.5. Canada
        • 8.2.5.1. Canada immuno-oncology therapy market revenue, by therapy type, 2016 – 2022 (USD Billion)
        • 8.2.5.2. Canada immuno-oncology therapy market revenue, by therapeutic area, 2016 – 2022 (USD Billion)
        • 8.2.5.3. Canada immuno-oncology therapy market revenue, by end-user, 2016 – 2022 (USD Billion)
      • 8.2.6. Rest of North America
        • 8.2.6.1. Rest of North America immuno-oncology therapy market revenue, by therapy type, 2016 – 2022 (USD Billion)
        • 8.2.6.2. Rest of North America immuno-oncology therapy market revenue, by therapeutic area, 2016 – 2022 (USD Billion)
        • 8.2.6.3. Rest of North America immuno-oncology therapy market revenue, by end-user, 2016 – 2022 (USD Billion)
    • 8.3. Europe
      • 8.3.1. Europe immuno-oncology therapy market revenue, by therapy type, 2016 – 2022 (USD Billion)
      • 8.3.2. Europe immuno-oncology therapy market revenue, by therapeutic area, 2016 – 2022 (USD Billion)
      • 8.3.3. Europe immuno-oncology therapy market revenue, by end-user, 2016 – 2022 (USD Billion)
      • 8.3.4. U.K.
        • 8.3.4.1. U.K. Immuno-oncology therapy market revenue, by therapy type, 2016 – 2022 (USD Billion)
        • 8.3.4.2. U.K. Immuno-oncology therapy market revenue, by therapeutic area, 2016 – 2022 (USD Billion)
        • 8.3.4.3. U.K. Immuno-oncology therapy market revenue, by end-user, 2016 – 2022 (USD Billion)
      • 8.3.5. Germany
        • 8.3.5.1. Germany immuno-oncology therapy market revenue, by therapy type, 2016 – 2022 (USD Billion)
        • 8.3.5.2. Germany immuno-oncology therapy market revenue, by therapeutic area, 2016 – 2022 (USD Billion)
        • 8.3.5.3. Germany immuno-oncology therapy market revenue, by end-user, 2016 – 2022 (USD Billion)
      • 8.3.6. France
        • 8.3.6.1. France immuno-oncology therapy market revenue, by therapy type, 2016 – 2022 (USD Billion)
        • 8.3.6.2. France immuno-oncology therapy market revenue, by therapeutic area, 2016 – 2022 (USD Billion)
        • 8.3.6.3. France immuno-oncology therapy market revenue, by end-user, 2016 – 2022 (USD Billion)
      • 8.3.7. Italy
        • 8.3.7.1. Italy immuno-oncology therapy market revenue, by therapy type, 2016 – 2022 (USD Billion)
        • 8.3.7.2. Italy immuno-oncology therapy market revenue, by therapeutic area, 2016 – 2022 (USD Billion)
        • 8.3.7.3. Italy immuno-oncology therapy market revenue, by end-user, 2016 – 2022 (USD Billion)
      • 8.3.8. Spain
        • 8.3.8.1. Spain immuno-oncology therapy market revenue, by therapy type, 2016 – 2022 (USD Billion)
        • 8.3.8.2. Spain immuno-oncology therapy market revenue, by therapeutic area, 2016 – 2022 (USD Billion)
        • 8.3.8.3. Spain immuno-oncology therapy market revenue, by end-user, 2016 – 2022 (USD Billion)
      • 8.3.9. Russia
        • 8.3.9.1. Russia immuno-oncology therapy market revenue, by therapy type, 2016 – 2022 (USD Billion)
        • 8.3.9.2. Russia immuno-oncology therapy market revenue, by therapeutic area, 2016 – 2022 (USD Billion)
        • 8.3.9.3. Russia immuno-oncology therapy market revenue, by end-user, 2016 – 2022 (USD Billion)
      • 8.3.10. Rest of Europe
        • 8.3.10.1. Rest of Europe immuno-oncology therapy market revenue, by therapy type, 2016 – 2022 (USD Billion)
        • 8.3.10.2. Rest of Europe immuno-oncology therapy market revenue, by therapeutic area, 2016 – 2022 (USD Billion)
        • 8.3.10.3. Rest of Europe immuno-oncology therapy market revenue, by end-user, 2016 – 2022 (USD Billion)
    • 8.4. Asia Pacific
      • 8.4.1. Asia Pacific immuno-oncology therapy market revenue, by therapy type, 2016 – 2022 (USD Billion)
      • 8.4.2. Asia Pacific immuno-oncology therapy market revenue, by therapeutic area, 2016 – 2022 (USD Billion)
      • 8.4.3. Asia Pacific immuno-oncology therapy market revenue, by end-user, 2016 – 2022 (USD Billion)
      • 8.4.4. China
        • 8.4.4.1. China immuno-oncology therapy market revenue, by therapy type, 2016 – 2022(USD Billion)
        • 8.4.4.2. China immuno-oncology therapy market revenue, by therapeutic area, 2016 – 2022 (USD Billion)
        • 8.4.4.3. China immuno-oncology therapy market revenue, by end-user, 2016 – 2022 (USD Billion)
      • 8.4.5. Japan
        • 8.4.5.1. Japan immuno-oncology therapy market revenue, by therapy type, 2016 – 2022 (USD Billion)
        • 8.4.5.2. Japan immuno-oncology therapy market revenue, by therapeutic area, 2016 – 2022 (USD Billion)
        • 8.4.5.3. Japan immuno-oncology therapy market revenue, by end-user, 2016 – 2022 (USD Billion)
      • 8.4.6. India
        • 8.4.6.1. India immuno-oncology therapy market revenue, by therapy type, 2016 – 2022 (USD Billion)
        • 8.4.6.2. India immuno-oncology therapy market revenue, by therapeutic area, 2016 – 2022 (USD Billion)
        • 8.4.6.3. India immuno-oncology therapy market revenue, by end-user, 2016 – 2022 (USD Billion)
      • 8.4.7. Australia
        • 8.4.7.1. Australia immuno-oncology therapy market revenue, by therapy type, 2016 – 2022 (USD Billion)
        • 8.4.7.2. Australia immuno-oncology therapy market revenue, by therapeutic area, 2016 – 2022 (USD Billion)
        • 8.4.7.3. Australia immuno-oncology therapy market revenue, by end-user, 2016 – 2022 (USD Billion)
      • 8.4.8. Rest of Asia Pacific
        • 8.4.8.1. Rest of Asia Pacific immuno-oncology therapy market revenue, by therapy type, 2016 – 2022 (USD Billion)
        • 8.4.8.2. Rest of Asia Pacific immuno-oncology therapy market revenue, by therapeutic area, 2016 – 2022 (USD Billion)
        • 8.4.8.3. Rest of Asia Pacific immuno-oncology therapy market revenue, by end-user, 2016 – 2022 (USD Billion)
    • 8.5. Latin America
      • 8.5.1. Latin America immuno-oncology therapy market revenue, by therapy type, 2016 – 2022 (USD Billion)
      • 8.5.2. Latin America immuno-oncology therapy market revenue, by therapeutic area, 2016 – 2022 (USD Billion)
      • 8.5.3. Latin America immuno-oncology therapy market revenue, by end-user, 2016 – 2022 (USD Billion)
      • 8.5.4. Brazil
        • 8.5.4.1. Brazil immuno-oncology therapy market revenue, by therapy type, 2016 – 2022 (USD Billion)
        • 8.5.4.2. Brazil immuno-oncology therapy market revenue, by therapeutic area, 2016 – 2022 (USD Billion)
        • 8.5.4.3. Brazil immuno-oncology therapy market revenue, by end-user, 2016 – 2022 (USD Billion)
      • 8.5.5. Mexico
        • 8.5.5.1. Mexico immuno-oncology therapy market revenue, by therapy type, 2016 – 2022 (USD Billion)
        • 8.5.5.2. Mexico immuno-oncology therapy market revenue, by therapeutic area, 2016 – 2022 (USD Billion)
        • 8.5.5.3. Mexico immuno-oncology therapy market revenue, by end-user, 2016 – 2022 (USD Billion)
      • 8.5.6. Argentina
        • 8.5.6.1. Argentina immuno-oncology therapy market revenue, by therapy type, 2016 – 2022 (USD Billion)
        • 8.5.6.2. Argentina immuno-oncology therapy market revenue, by therapeutic area, 2016 – 2022 (USD Billion)
        • 8.5.6.3. Argentina immuno-oncology therapy market revenue, by end-user, 2016 – 2022 (USD Billion)
      • 8.5.7. Rest of Latin America
        • 8.5.7.1. Rest of Latin America immuno-oncology therapy market revenue, by therapy type, 2016 – 2022 (USD Billion)
        • 8.5.7.2. Rest of Latin America immuno-oncology therapy market revenue, by therapeutic area, 2016 – 2022 (USD Billion)
        • 8.5.7.3. Rest of Latin America immuno-oncology therapy market revenue, by end-user, 2016 – 2022 (USD Billion)
    • 8.6. Middle East and Africa
      • 8.6.1. Middle East and Africa immuno-oncology therapy market revenue, by therapy type, 2016 – 2022 (USD Billion)
      • 8.6.2. Middle East and Africa immuno-oncology therapy market revenue, by therapeutic area, 2016 – 2022 (USD Billion)
      • 8.6.3. Middle East and Africa immuno-oncology therapy market revenue, by end-user, 2016 – 2022 (USD Billion)
      • 8.6.4. Saudi Arabia
        • 8.6.4.1. Saudi Arabia immuno-oncology therapy market revenue, by therapy type, 2016 – 2022 (USD Billion)
        • 8.6.4.2. Saudi Arabia immuno-oncology therapy market revenue, by therapeutic area, 2016 – 2022 (USD Billion)
        • 8.6.4.3. Saudi Arabia immuno-oncology therapy market revenue, by end-user, 2016 – 2022 (USD Billion)
      • 8.6.5. UAE
        • 8.6.5.1. UAE immuno-oncology therapy market revenue, by therapy type, 2016 – 2022 (USD Billion)
        • 8.6.5.2. UAE immuno-oncology therapy market revenue, by therapeutic area, 2016 – 2022 (USD Billion)
        • 8.6.5.3. UAE immuno-oncology therapy market revenue, by end-user, 2016 – 2022 (USD Billion)
      • 8.6.6. Qatar
        • 8.6.6.1. Qatar immuno-oncology therapy market revenue, by therapy type, 2016 – 2022 (USD Billion)
        • 8.6.6.2. Qatar immuno-oncology therapy market revenue, by therapeutic area, 2016 – 2022 (USD Billion)
        • 8.6.6.3. Qatar immuno-oncology therapy market revenue, by end-user, 2016 – 2022 (USD Billion)
      • 8.6.7. South Africa
        • 8.6.7.1. South Africa immuno-oncology therapy market revenue, by therapy type, 2016 – 2022 (USD Billion)
        • 8.6.7.2. South Africa immuno-oncology therapy market revenue, by therapeutic area, 2016 – 2022 (USD Billion)
        • 8.6.7.3. South Africa immuno-oncology therapy market revenue, by end-user, 2016 – 2022 (USD Billion)
      • 8.6.8. Rest of Middle East and Africa
        • 8.6.8.1. Rest of Middle East and Africa immuno-oncology therapy market revenue, by therapy type, 2016 – 2022 (USD Billion)
        • 8.6.8.2. Rest of Middle East and Africa immuno-oncology therapy market revenue, by therapeutic area, 2016 – 2022 (USD Billion)
        • 8.6.8.3. Rest of Middle East and Africa immuno-oncology therapy market revenue, by end-user, 2016 – 2022 (USD Billion)
  • Chapter 9. Company Profile
    • 9.1. Amgen, Inc.
      • 9.1.1. Overview
      • 9.1.2. Financials
      • 9.1.3. Therapy portfolio
      • 9.1.4. Business strategy
      • 9.1.5. Recent developments
    • 9.2. AstraZeneca Plc.
      • 9.2.1. Overview
      • 9.2.2. Financials
      • 9.2.3. Therapy portfolio
      • 9.2.4. Business strategy
      • 9.2.5. Recent developments
    • 9.3. Bristol-Myers Squibb Company
      • 9.3.1. Overview
      • 9.3.2. Financials
      • 9.3.3. Therapy portfolio
      • 9.3.4. Business strategy
      • 9.3.5. Recent developments
    • 9.4. Eli Lilly and Company
      • 9.4.1. Overview
      • 9.4.2. Financials
      • 9.4.3. Therapy portfolio
      • 9.4.4. Business strategy
      • 9.4.5. Recent developments
    • 9.5. F.Hoffmann-La Roche Ltd.
      • 9.5.1. Overview
      • 9.5.2. Financials
      • 9.5.3. Therapy portfolio
      • 9.5.4. Business strategy
      • 9.5.5. Recent developments
    • 9.6. GlaxoSmithKline Plc.
      • 9.6.1. Overview
      • 9.6.2. Financials
      • 9.6.3. Therapy portfolio
      • 9.6.4. Business strategy
      • 9.6.5. Recent developments
    • 9.7. Janssen Biotech
      • 9.7.1. Overview
      • 9.7.2. Financials
      • 9.7.3. Therapy portfolio
      • 9.7.4. Business strategy
      • 9.7.5. Recent developments
    • 9.8. Merck and Co.
      • 9.8.1. Overview
      • 9.8.2. Financials
      • 9.8.3. Therapy portfolio
      • 9.8.4. Business strategy
      • 9.8.5. Recent developments
    • 9.9. Novartis AG
      • 9.9.1. Overview
      • 9.9.2. Financials
      • 9.9.3. Therapy portfolio
      • 9.9.4. Business strategy
      • 9.9.5. Recent developments
    • 9.10. Pfizer, Inc.
      • 9.10.1. Overview
      • 9.10.2. Financials
      • 9.10.3. Therapy portfolio
      • 9.10.4. Business strategy
      • 9.10.5. Recent developments
    • 9.11. Sanofi
      • 9.11.1. Overview
      • 9.11.2. Financials
      • 9.11.3. Therapy portfolio
      • 9.11.4. Business strategy
      • 9.11.5. Recent developments
    • 9.12. Spectrum Pharmaceuticals, Inc.
      • 9.12.1. Overview
      • 9.12.2. Financials
      • 9.12.3. Therapy portfolio
      • 9.12.4. Business strategy
      • 9.12.5. Recent developments
    • 9.13. Takeda Pharmaceuticals
      • 9.13.1. Overview
      • 9.13.2. Financials
      • 9.13.3. Therapy portfolio
      • 9.13.4. Business strategy
      • 9.13.5. Recent developments

Methodology

This report is based on in-depth qualitative and quantitative analyses of the global Immuno-oncology Therapy market. Zion Research has collected and analyzed key data belong to the global Immuno-oncology Therapy market using a variety of methods. Quantitative analysis has been done following various projection and sampling techniques.

The qualitative analysis involved primary interviews, surveys, and vendor briefings. The data gathered as a result of these processes were validated through experts' opinions. The market dynamics have been determined after conducting a detailed study of the micro and macroeconomic indicators of the market.

Various parameters have been taken into account, while estimating market size. The revenue generated by the leading industry participants in from the sales of Immuno-oncology Therapy across the world has been calculated through primary and secondary research.

Zion Research employs the combination of secondary research followed by extensive primary research. Under secondary research, we refer to prominent paid as well as open access data sources including product literature, company annual reports, government publications, press releases, industry association’s magazines and other relevant sources for data collection. Other prominent secondary sources include STATISTA, trade journals, trade associations, statistical data from government websites, etc. 

For this study, Zion Research has conducted all-encompassing primary research with key industry participants to collect first had data. Moreover, in-depth interviews with key opinion leaders also assisted in validation of findings from secondary research and to understand key trends in the Immuno-oncology Therapy industry. Primary research makes up the major source of data collection and validation.   

Primary Research

We conduct primary interviews with industry participants and commentators on an ongoing basis to validate data and analysis. A typical research interview fulfills the following functions:

  • Provides firsthand information on market size, market trends, growth trends, competitive landscape, outlook, etc.
  • Helps in validating and strengthening the secondary research findings
  • Further, develops the analysis team’s expertise and market understanding
  • Primary research involves e-mail interactions, telephonic interviews as well as face-to-face interviews for each market, category, segment and sub-segment across geographies

Participants who typically participate in such a process include, but are not limited to:

  • Industry participants: CEOs, VPs, marketing/product managers, market intelligence managers and national sales managers
  • Purchasing managers, technical personnel, distributors and resellers
  • Outside experts: Investment bankers, valuation experts and research analysts specializing in specific markets

Key opinion leaders specializing in different areas corresponding to different industry verticals

Secondary Research

Secondary research sources that are typically referred to include, but are not limited to:

  • Company websites, annual reports, financial reports, broker reports, investor presentations and SEC filings
  • IDC and other relevant magazines
  • Internal and external proprietary databases, and relevant patent and regulatory databases
  • National government documents, statistical databases and market reports

News articles, press releases and webcasts specific to companies operating in the market

Following a comprehensive secondary and primary research and insights thus gathered, analysts at Zion Research have provided an in-depth analysis of various aspects of the Immuno-oncology Therapy market.

Models

Where no hard data is available, we use models and estimates to produce comprehensive data sets. A rigorous methodology is adopted, wherein the available hard data is cross-referenced with the following data types to produce estimates:

  • Demographic data: Population split by segments
  • Macroeconomic indicators: GDP, PPP, Per Capita Income, etc.
  • Industry indicators: Expenditure, technology stage and infrastructure, sector growth and facilities
  • Data is then cross-checked by an expert panel.

Free Analysis

The next generation of drugs to treat cancer involves stimulating a person’s own immune system to selectively attack cancer cells while keeping normal cells unaffected, or delivering certain immune system components in order to inhibit the spread of cancer effectively. One of the hallmarks of certain types of cancers is the suppression of the body's immune system, rendering it unable to fight the disease. These therapies have shown great promise in several clinical trials as well as in patients currently being treated. The technological advancements are helping the growth of immuno-oncology therapy market. The biotechnology and pharmaceutical companies are striving to launch new and most effective therapies in the market.

The key factors that drive the growth of immuno-oncology market include rise in incidence & prevalence of cancer, technological advancements in treatment therapies, increase in number of R&D for the treatment of cancer, and specificity & effectiveness of cancer immunotherapy for the treatment of wide range of cancers such as lung cancer, breast cancer, skin cancer, and others. In addition, the rise in healthcare expenditure and healthcare insurance are expected to fuel the market growth during the forecast period. However, shortage of experienced healthcare professionals and lack of awareness among the population restricts market growth.

Global Immuno oncology Therapy Market

Based on therapy type immuno-oncology therapy market has been segmented into monoclonal antibodies, immune system modulators, cancer vaccines and others. Immune checkpoint inhibitors are further segmented into PD1/ PDL1 and CTLA-4. On the basis of the therapeutic area, the market for immuno-oncology therapy is segmented into lung cancer, colorectal cancer, breast cancer, prostate cancer, melanoma, blood cancer and other cancers. Based on end-user the immuno-oncology therapy market is segmented into hospitals, clinics, ambulatory surgical centers (ASC’S) and cancer research institutes.  

Over the last few years, North America and Europe have been the major contributors in the global immuno-oncology therapy market due to their reputation as a suitable place for research and development. The market for cancer immunotherapy has a huge demand in both region and is expected to grow in coming future. However, the global population witnessed an alarming surge in diagnosed cancer cases. For instance, according to GLOBOCAN, 14.1 million new cancer cases were diagnosed worldwide in 2012. According to WHO, the growth in cancer incidence is expected to increase by 70% over the next two decades with 22 million new cancer cases. Cancer is highly prevalent in lower and middle-income countries as they lack suitable healthcare infrastructure to effectively combat the condition. For instance, according to GLOBOCAN, 57% of 14.1 million new cancer patients diagnosed worldwide in 2012 were from less developed regions. Similarly, 65% of the total worldwide death related to cancer was reported from less developed regions.

Some of the key players in immuno-oncology therapy market include Amgen, Inc., AstraZeneca Plc., Bristol-Myers Squibb Company, Eli-Lilly and Company, F.Hoffmann-La Roche Ltd., GlaxoSmithKline Plc., Janssen Biotech, Inc., Merck and Co., Novartis AG, Pfizer, Inc., Sanofi, Spectrum Pharmaceuticals and Takeda Pharmaceuticals. Currently, the market’s growth rate is very high, which has encouraged the leading players to focus on consolidation through product licensing and long-term partnerships in order to gain maximum share in the market.

Office Address

Corporate Office
Zion Market Research 244 Fifth Avenue, Suite N202 New York, 10001, United States
Tel: +49-322 210 92714
USA/Canada Toll Free No.1-855-465-4651

Asia Pacific Office
3rd Floor, Mrunal Paradise, Opp Maharaja Hotel, Pimple Gurav, Pune 411061, Maharashtra, India
Phone No 020-46277770

Contact #
US OFFICE NO +1-386-310-3803
US/CAN TOLL FREE +1-855-465-4651
Email: sales@zionmarketresearch.com

We Accept

We have secured system to process your transaction.


We Are On Social